Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Condition:   HR+ HER2- Postmenopausal Advanced Breast CancerInterventions:   Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant;   Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapySponsor:   Novartis PharmaceuticalsRecruiting - verified April 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials